List view / Grid view
Can targeting both regulatory and inflammatory pathways change how we treat neurodegenerative disease? Coya Therapeutics is testing that idea with its IL-2 and GLP-1 receptor agonist combination.
Nature’s pharmacy has yielded half of today’s medicines, yet most of its potential remains untapped. AI is now changing how quickly new therapies can be found.
Drug discovery now costs 100 times more per FDA-approved drug than in 1950, despite vast advances in biology and computing. The core problem is the collapse of predictive validity in preclinical models, which sits at the heart of pharma’s productivity paradox.
Measuring disease progression remains one of the biggest hurdles in CNS drug development. Eye movements, now trackable with just a laptop and webcam, are emerging as a sensitive and scalable biomarker that could transform how trials are designed and therapies reach patients.
A new fibre-optic method lets researchers monitor amyloid plaque buildup in living, freely moving mice – offering a minimally invasive way to track Alzheimer’s disease progression and test potential therapies.
New therapeutic approaches are emerging for CNS disorders – but can they overcome the toughest barriers in drug development? Find out what is driving progress and what still stands in the way.
Single-cell and spatial technologies are giving researchers an unprecedented view of how brain diseases like Alzheimer’s really work. The result? Faster discovery, clearer targets and a new path towards more effective treatments.
Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
Gene silencing offers a promising approach to treating rare neurological diseases like H-ABC. With clinical trials on the horizon, find out how targeted therapies could bring real hope to patients and families.
US researchers say new mechanism could lead to new drugs and therapies to treat normal cognitive decline in aging.
Individuals with higher levels of lean muscle may have a reduced risk of developing Alzheimer's disease. While further research is needed to understand the underlying biological pathways and implications for clinical practice, these findings shed light on the potential role of lean muscle in protecting brain health.
Using rodent models, the researchers emphasized the potential of newly generated neurons in adulthood to serve as therapy for addressing the functional deficits and pathology associated with Alzheimer's disease.
Researchers have found a way to ensure that new Alzheimer’s medications are delivered to the right place in the body and at the right timepoint in disease progression, so that they have the best effect.
Scientists from Rice University are using fluorescence lifetime to shed new light on a peptide associated with Alzheimer’s disease.
In this article, Drug Target Review’s Izzy Wood and Ria Kakkad share some of the most ground-breaking moments from drug discovery this year.
